ClinicalTrials.gg
CompletedNCT00279045Updated Nov 29, 2017

Diabetes Study With Rosiglitazone Monotherapy Versus Metformin Or Glyburide/Glibenclamide

A Phase 3 interventional study of Rosiglitazone and glyburide in Diabetes Mellitus, Type 2, sponsored by GlaxoSmithKline. Completed at 490 sites in 17 countries. Open to participants aged 30 Years to 75 Years. Per ClinicalTrials.gov, last updated 2017-11-29.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
4,426
Allocation
Randomized
Ages
30 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 52 studies testing rosiglitazone in Diabetes Mellitus, Type 2 — none open to participants now, none under way, none of them phase 3. Rosiglitazone · Diabetes Mellitus, Type 2.

Enrollment
2nd of 51
4,426 · median 149
Started
2000
with 5 others
Phase 3
21 of 52
none open now
Registered
15th of 52
by date
Lead sponsor
22 of 52
GlaxoSmithKline

Among the 52 studies testing rosiglitazone in Diabetes Mellitus, Type 2, this one is the 2nd largest by enrollment of the 51 interventional ones that give a count, is one of 6 that started in 2000, is one of 21 in phase 3, and was the 15th registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

None of the 52 studies testing rosiglitazone in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →

About rosiglitazone

Rosiglitazone: first FDA approval 1999 (AVANDIA), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 30 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 52 studies testing rosiglitazone in Diabetes Mellitus, Type 2 as a file.
02

Study summary

The study will compare and evaluate the effects of long-term treatment of monotherapy with rosiglitazone, metformin and glyburide/glibenclamide on the improvement and maintenance of glycemic control in patients with recently diagnosed type 2 diabetes mellitus.

03

Conditions studied

  • Diabetes Mellitus, Type 2

Keywords

  • type 2 diabetes monotherapy treatment naive
04

Who can participate

Ages eligible
30 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Newly diagnosed patients (\< 3years) with type 2 diabetes.
  • Fasting plasma glucose (FPG) range of 126-240 mg/dL at Screening.
  • No previous treatment with oral or parenteral glucose-lowering therapy.

Exclusion criteria

Exclusion criteria:

  • History of lactic acidosis.
  • Anemia (\<11g for males, \<10 g for females).
  • Unstable or severe NY Heart Association-class 3 or 4.
  • Any NY Heart Association congestive heart failure.
  • Patients with chronic diseases requiring periodic or intermittent treatment with oral or intravenous .
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Enrollment
4,426 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. Time from randomization to the primary action point (monotherapy failure).

Secondary outcomes

  1. Comparison of effects of long-term treatment with Rosiglitazone, Metformin, Glyburide: - maintenance/restoration of beta-cell function: HOMA IS, progression of microalbuminuria, fibrinolytic markers (PAI-1,fibrinogen, CRP).

07

Study locations

490 sites
  • GSK Investigational Site
    Anniston, Alabama 36207, United States
  • GSK Investigational Site
    Birmingham, Alabama 35233, United States
  • GSK Investigational Site
    Mesa, Arizona 85206, United States
  • GSK Investigational Site
    Tucson, Arizona 85723, United States
  • GSK Investigational Site
    Little Rock, Arkansas 77205, United States
  • GSK Investigational Site
    Berkeley, California 94705, United States
  • GSK Investigational Site
    Corona, California 92879, United States
  • GSK Investigational Site
    Fair Oaks, California 95628, United States
  • GSK Investigational Site
    Fremont, California 94538, United States
  • GSK Investigational Site
    Fresno, California 93720, United States
  • GSK Investigational Site
    Fullerton, California 92835, United States
  • GSK Investigational Site
    Greenbrae, California 94904, United States
  • GSK Investigational Site
    Harbor City, California 90710, United States
  • GSK Investigational Site
    Healdsburg, California 95448, United States
  • GSK Investigational Site
    La Jolla, California 92037, United States
  • GSK Investigational Site
    Loma Linda, California 92354, United States
  • GSK Investigational Site
    Los Angeles, California 90059, United States
  • GSK Investigational Site
    Los Angeles, California 90095, United States
  • GSK Investigational Site
    Modesto, California 95355, United States
  • GSK Investigational Site
    Pasadena, California 91105, United States
  • GSK Investigational Site
    San Diego, California 92126, United States
  • GSK Investigational Site
    San Francisco, California 94143, United States
  • GSK Investigational Site
    Santa Rosa, California 95405, United States
  • GSK Investigational Site
    Sunnyvale, California 94086, United States
  • GSK Investigational Site
    Ukiah, California 95482, United States
  • GSK Investigational Site
    Walnut Creek, California 94598, United States
  • GSK Investigational Site
    Yorba Linda, California 92886, United States
  • GSK Investigational Site
    Boulder, Colorado 80304, United States
  • GSK Investigational Site
    Denver, Colorado 80209, United States
  • GSK Investigational Site
    Denver, Colorado 80220, United States
  • GSK Investigational Site
    Englewood, Colorado 80110, United States
  • GSK Investigational Site
    Longmont, Colorado 80501, United States
  • GSK Investigational Site
    Wheat Ridge, Colorado 80033, United States
  • GSK Investigational Site
    Wheat Ridge, Colorado 80043, United States
  • GSK Investigational Site
    Washington, District of Columbia 20003, United States
  • GSK Investigational Site
    Washington, District of Columbia 20037, United States
  • GSK Investigational Site
    Fort Myers, Florida 33907, United States
  • GSK Investigational Site
    Hollywood, Florida 33023, United States
  • GSK Investigational Site
    Jacksonville, Florida 32204, United States
  • GSK Investigational Site
    Jacksonville, Florida 32216, United States
  • GSK Investigational Site
    Melbourne, Florida 32935, United States
  • GSK Investigational Site
    Miami, Florida 33136, United States
  • GSK Investigational Site
    Miami, Florida 33176, United States
  • GSK Investigational Site
    Orlando, Florida 32806, United States
  • GSK Investigational Site
    Palm Harbor, Florida 34683, United States
  • GSK Investigational Site
    Saint Petersburg, Florida 33702, United States
  • GSK Investigational Site
    Saint Petersburg, Florida 33710, United States
  • GSK Investigational Site
    Sarasota, Florida 34239, United States
  • GSK Investigational Site
    Tampa, Florida 33612, United States
  • GSK Investigational Site
    Titusville, Florida 32796, United States
  • GSK Investigational Site
    West Palm Beach, Florida 33401, United States
  • GSK Investigational Site
    Atlanta, Georgia 30308, United States
  • GSK Investigational Site
    Atlanta, Georgia 30312, United States
  • GSK Investigational Site
    Atlanta, Georgia 30322, United States
  • GSK Investigational Site
    Atlanta, Georgia 30328, United States
  • GSK Investigational Site
    Atlanta, Georgia 30338, United States
  • GSK Investigational Site
    Blue Ridge, Georgia 30513, United States
  • GSK Investigational Site
    Dunwoody, Georgia 30338, United States
  • GSK Investigational Site
    Fayetteville, Georgia 30214, United States
  • GSK Investigational Site
    Honolulu, Hawaii 96813, United States
  • GSK Investigational Site
    Boise, Idaho 83706, United States
  • GSK Investigational Site
    Chicago, Illinois 60612, United States
  • GSK Investigational Site
    Gurnee, Illinois 60031, United States
  • GSK Investigational Site
    Springfield, Illinois 62704, United States
  • GSK Investigational Site
    Evansville, Indiana 47713, United States
  • GSK Investigational Site
    Indianapolis, Indiana 46202, United States
  • GSK Investigational Site
    Indianapolis, Indiana 46250, United States
  • GSK Investigational Site
    Lexington, Kentucky 40504-2681, United States
  • GSK Investigational Site
    Lake Charles, Louisiana 70601, United States
  • GSK Investigational Site
    New Orleans, Louisiana 70119, United States
  • GSK Investigational Site
    Slidell, Louisiana 70458, United States
  • GSK Investigational Site
    Slidell, Louisiana 70461, United States
  • GSK Investigational Site
    Bangor, Maine 04401, United States
  • GSK Investigational Site
    Baltimore, Maryland 21201, United States
  • GSK Investigational Site
    Baltimore, Maryland 21204, United States
  • GSK Investigational Site
    Baltimore, Maryland 21205, United States
  • GSK Investigational Site
    Baltimore, Maryland 21208, United States
  • GSK Investigational Site
    Boston, Massachusetts 02114, United States
  • GSK Investigational Site
    Springfield, Massachusetts 01199, United States
  • GSK Investigational Site
    Ann Arbor, Michigan 48109, United States
  • GSK Investigational Site
    Detroit, Michigan 48201, United States
  • GSK Investigational Site
    Lansing, Michigan 48912, United States
  • GSK Investigational Site
    Royal Oak, Michigan 48073, United States
  • GSK Investigational Site
    Minneapolis, Minnesota 55404, United States
  • GSK Investigational Site
    Minneapolis, Minnesota 55407-3799, United States
  • GSK Investigational Site
    Minneapolis, Minnesota 55416, United States
  • GSK Investigational Site
    Jackson, Mississippi 39202, United States
  • GSK Investigational Site
    Olive Branch, Mississippi 38654, United States
  • GSK Investigational Site
    Kansas City, Missouri 64132, United States
  • GSK Investigational Site
    Saint Louis, Missouri 63110, United States
  • GSK Investigational Site
    Saint Louis, Missouri 63128, United States
  • GSK Investigational Site
    Billings, Montana 59102, United States
  • GSK Investigational Site
    Omaha, Nebraska 68105, United States
  • GSK Investigational Site
    Omaha, Nebraska 68131, United States
  • GSK Investigational Site
    Henderson, Nevada 89014, United States
  • GSK Investigational Site
    Cherry Hill, New Jersey 08034, United States
  • GSK Investigational Site
    Cherry Hill, New Jersey 8034, United States
  • GSK Investigational Site
    Albuquerque, New Mexico 87102, United States
  • GSK Investigational Site
    Albuquerque, New Mexico 87106, United States
  • GSK Investigational Site
    Albuquerque, New Mexico 87109, United States

Showing the first 100 of 490 sites across 17 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Viberti G, Kahn SE, Greene DA, Herman WH, Zinman B, Holman RR, Haffner SM, Levy D, Lachin JM, Berry RA, Heise MA, Jones NP, Freed MI. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care. 2002 Oct;25(10):1737-43. doi: 10.2337/diacare.25.10.1737. PubMed 12351470 ↗
  • Viberti G, Lachin J, Holman R, Zinman B, Haffner S, Kravitz B, Heise MA, Jones NP, O'Neill MC, Freed MI, Kahn SE, Herman WH; ADOPT Study Group. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of Type 2 diabetic patients in North America and Europe. Diabet Med. 2006 Dec;23(12):1289-94. doi: 10.1111/j.1464-5491.2006.02022.x. PubMed 17116177 ↗
  • Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B, Viberti G; ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006 Dec 7;355(23):2427-43. doi: 10.1056/NEJMoa066224. Epub 2006 Dec 4. Erratum In: N Engl J Med. 2007 Mar 29;356(13):1387-8. PubMed 17145742 ↗
  • Kahn SE, Zinman B, Haffner SM, O'Neill MC, Kravitz BG, Yu D, Freed MI, Herman WH, Holman RR, Jones NP, Lachin JM, Viberti GC; ADOPT Study Group. Obesity is a major determinant of the association of C-reactive protein levels and the metabolic syndrome in type 2 diabetes. Diabetes. 2006 Aug;55(8):2357-64. doi: 10.2337/db06-0116. PubMed 16873701 ↗
  • Zinman B, Kahn SE, Haffner SM, O'Neill MC, Heise MA, Freed MI; ADOPT Study Group. Phenotypic characteristics of GAD antibody-positive recently diagnosed patients with type 2 diabetes in North America and Europe. Diabetes. 2004 Dec;53(12):3193-200. doi: 10.2337/diabetes.53.12.3193. PubMed 15561950 ↗
  • Gnesin F, Thuesen ACB, Kahler LKA, Madsbad S, Hemmingsen B. Metformin monotherapy for adults with type 2 diabetes mellitus. Cochrane Database Syst Rev. 2020 Jun 5;6(6):CD012906. doi: 10.1002/14651858.CD012906.pub2. PubMed 32501595 ↗
  • Lachin JM, Viberti G, Zinman B, Haffner SM, Aftring RP, Paul G, Kravitz BG, Herman WH, Holman RR, Kahn SE; ADOPT Study Group. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clin J Am Soc Nephrol. 2011 May;6(5):1032-40. doi: 10.2215/CJN.09291010. Epub 2011 Mar 31. PubMed 21454723 ↗
  • Kahn SE, Haffner SM, Viberti G, Herman WH, Lachin JM, Kravitz BG, Yu D, Paul G, Holman RR, Zinman B; Diabetes Outcome Progression Trial (ADOPT) Study Group. Rosiglitazone decreases C-reactive protein to a greater extent relative to glyburide and metformin over 4 years despite greater weight gain: observations from a Diabetes Outcome Progression Trial (ADOPT). Diabetes Care. 2010 Jan;33(1):177-83. doi: 10.2337/dc09-1661. Epub 2009 Oct 6. PubMed 19808911 ↗
  • Kahn SE, Zinman B, Lachin JM, Haffner SM, Herman WH, Holman RR, Kravitz BG, Yu D, Heise MA, Aftring RP, Viberti G; Diabetes Outcome Progression Trial (ADOPT) Study Group. Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care. 2008 May;31(5):845-51. doi: 10.2337/dc07-2270. Epub 2008 Jan 25. PubMed 18223031 ↗

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2000, a primary completion of Jun 2006 and a completion of Jun 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 17, 2006
First posted
Jan 19, 2006
Start
Jan 3, 2000
Primary completionActual
Jun 1, 2006
CompletionActual
Jun 19, 2006
Last update
Nov 29, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 29, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00279045
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jan 19, 2006
Start date
Jan 3, 2000
Primary completion
Jun 1, 2006
Completion
Jun 19, 2006
Last update
Nov 29, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Rosiglitazone · Glyburide · Metformin

Start the discussion